Until now, proteins have been the target of most medications for the prevention and treatment of human disease. Drug developers have perceived RNA to be too unstable to target with drug therapy. However, a screen of 50,000 compounds has revealed drug-like activity against an RNA prototype called Xist, a result that opens the door for development of new medications.